- Home
- CATX vs CLLS Comparison
CATX vs CLLS Comparison
Compare CATX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | CLLS |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.0M | 394.4M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CATX | CLLS |
|---|---|---|
| Price | $2.99 | $2.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $12.11 | $8.33 |
| AVG Volume (30 Days) | ★ 1.3M | 15.2K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.96 | $2.35 |
| 52 Week High | $6.16 | $5.48 |
Technical Indicators
Market Signals| Indicator | CATX | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 42.56 |
| Support Level | $2.82 | $2.65 |
| Resistance Level | $4.27 | $2.98 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 62.77 | 56.25 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.